91大神

Dr. Medow is a Tenured Professor of Neurological Surgery, Neurology, and Biomedical Engineering at the 91大神 College of Wisconsin. He is the Director of Neurocritical Care, Neurotrauma, and the Chief of Inpatient Operations in the department of Neurology. He has active practices in neurosurgery and critical care. Dr. Medow served as the Director of Neurocritical Care and the Vice Chair of Quality at the University of Wisconsin Hospital in Madison from 2008-2023. In his first year as faculty, the neurocritical care program that he founded reduced mortality by 43% in the sickest patients and simultaneously saved nearly $3 million in direct costs.

Dr. Medow received his BS degree from the University of Illinois Urbana-Champaign in 1995, his MD degree from the University of Illinois Chicago in 1999, an MSc degree in Clinical Investigation from University of Wisconsin Madison in 2010, and his PhD in Clinical Investigation / Informatics in 2019. He completed his residency in neurosurgery, training in critical care medicine, and fellowship in endovascular neurosurgery at the University of Wisconsin School of Medicine and Public Health in 2006 and 2008 respectively. He is quadruple boarded in neurosurgery, neurocritical care neurology, neurocritical care neurosurgery, and clinical informatics.

Dr. Medow has received numerous awards for excellent patient care and for teaching and research. His clinical focus is on improving outcomes and reducing costs in healthcare. His lab is formed by a multidisciplinary group of people that come from engineering, computer science, informatics, and the allied health professionals that care for patients at the bedside. He has presented in many forums about complex case management. His translational research focuses device development and on AI decision support algorithm development. His work in AI has culminated in a software product known as the Digital Intern which improves quality and cost savings in value driven healthcare delivery through a standard approach to personalized medicine. Dr. Medow’s other technologies are used in three other startup companies. The first, Madison Scientific, produces a new smart CSF shunt that measures ICP remotely and permits complex drainage functions to help patients with hydrocephalus, particularly those with slit ventricles, eliminate siphoning and drain CSF effectively for their personalized needs. The second company, Neurlogix, is developing a highly customizable, safer, and less work intensive device to drain CSF from extraventricular and lumbar drains using existing catheters at less cost than the current state of the art. The final company is developing a bite block that protects the front teeth and tongue in patients who have an endotracheal tube in place.